abstract |
A method for determining the efficacy of a GPC3 target therapeutic regimen for cancer in a patient or patient prior to receiving a GPC3 target therapeutic treatment or for determining the continuation of a GPC3 target therapeutic regimen for a patient, And / or a method for measuring the number of immune cells in a biological sample isolated from a patient who has received treatment with a GPC3 target therapeutic agent or the expression level of a molecule expressed on the immune cell, wherein, when the number of cells or the expression level is a predetermined value A method for determining that the GPC3 target therapeutic regimen is effective, or for determining the continuation of the GPC3 target therapeutic regimen is disclosed. Also disclosed is a GPC3 targeted therapeutic agent or agent for administration to a patient for whom a GPC3 target therapeutic regimen is determined to be effective, or where it is determined to continue treatment with a GPC3 target therapeutic agent. |